Cardiovascular safety of β2-adrenoceptor agonist use in patients with obstructive airway disease: A systematic review

Drugs and Aging

Volumn 21, Issue 6, 2004, Pages 405-414

  Salpeter, Shelley R ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; POTASSIUM;

ADULT; ASTHMA; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG SAFETY; DRUG USE; ECG ABNORMALITY; HEART ARREST; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART PALPITATION; HEART RATE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; OBSTRUCTIVE AIRWAY DISEASE; PRIORITY JOURNAL; REVIEW; SINUS TACHYCARDIA; SUDDEN DEATH; SYNCOPE; SYSTEMATIC REVIEW; THORAX PAIN;

ADRENERGIC BETA-AGONISTS; ANIMALS; ASTHMA; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 2442520518     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421060-00005     Document Type: Review

References (101)

1. Bristow MR. β-adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101: 558-69
2. Ablad B, Carlsson E, Dahlof C, et al. Pharmacology of β-adrenoceptor blocking drugs: some aspects of the pharmacology of β-adrenoceptor blockers. Drugs 1976: 11 Suppl. 1: 100-11
3. Johnson M. The β-adrenoceptor. Am J Respir Crit Care Med 1998; 158 (5 Pt 3): S146-53
4. Nishikawa M, Mak JCW, Barnes PJ. Effect of short- and long-acting β2-adrenoceptor agonists on pulmonary β2-adrenoceptor expression in human lung. Eur J Pharmacol 1996; 318: 123-9
5. Bhagat R, Kalra S, Swystun VA, et al. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108 (5): 1235-9
6. Pansegrouw DF, Weich DJV, Le Roux FPJ. β-adrenergic receptor tachyphylaxis in acute severe asthma: a preliminary communication. S Afr Med J 1991; 80 (7): 229-30
7. Brodde O-E. Pathophysiology of the β-adrenoceptor system in chronic heart failure: consequences for treatment with agonists, partial agonists or antagonists? Eur Heart J 1991; 12 Suppl. F: 54-62
8. Wadworth AN, Murdoch D, Brogden RN. Atenolol: a reappraisal of its pharmacologic properties and therapeutic use in cardiovascular disorders. Drugs 1991; 42: 568-10
9. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730-7
10. Aurbach AD, Goldman L. β-blockers and reduction of cardiac events in noncardiac surgery: scientific review. JAMA 2002; 287 (11): 1435-44
11. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-20
12. Steinbeck G, Andresen D, Bach P, et al. A comparison of electrophysiologically guided antiarrhythmic drug therapy with β-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. N Engl J Med 1992; 327: 987-92
13. Sears MR. Adverse effects of β-agonists. J Allergy Clin Immunol 2002; 110 (6 Suppl.): S322-8
14. Chatterjee K, De Marco T. Role of nonglycosidic inotropic agents: indications, ethics, and limitations. Med Clin North Am 2003; 87 (2): 391-418
15. Lulich KM, Goldie RG, Ryan G, et al. Adverse reactions to β2-agonist bronchodilators. Med Toxicol 1986; 1 (4): 286-99
16. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of β-agonists in patients with asthma and chronic obstructive pulmonary disease: a meta-analysis. Chest. In press
17. Au DH, Lemaitre RN, Curtis JR, et al. The risk of myocardial infarction associated with inhaled β-adrenoceptor agonists. Am J Respir Crit Care Med 2000; 161: 827-30
18. Au DH, Curtis JR, McDonell MB, et al. Association between inhaled β-agonists and the risk of unstable angina and myocardial infarction. Chest 2002; 121: 846-51
19. Suissa S, Assimes T, Ernst P. Inhaled short acting β-agonist use in COPD and the risk of acute myocardial infarction. Thorax 2003; 58: 43-6
20. Coughlin SS, Metayer C, McCarthy EP, et al. Respiratory illness, β-agonists, and risk of idiopathic dilated cardiomyopathy. Am J Epidemiol 1995; 142 (4): 395-403
21. Martin RM, Dunn NR, Freemantle SN, et al. Risk of non-fatal cardiac failure and ischaemic heart disease with long acting β2-agonists. Thorax 1998; 53 (7): 558-62
22. Sengstock DM, Obeidat O, Pasnoori V, et al. Asthma, β-agonists, and development of congestive heart failure: results of the ABCHF Study. J Card Fail 2002; 8 (4): 232-8
23. Lemaitre RN, Siscovick DS, Psaty BM, et al. Inhaled β-2 adrenergic receptor agonists and primary cardiac arrest. Am J Med 2002; 113: 711-6
24. Suissa S, Hemmelgarn B, Blais L, et al. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med 1996; 154: 1598-602
25. Bennett JA, Smyth ET, Pavord ID, et al. Systemic effects of salbutamol and salmeterol in patients with asthma. Thorax 1994; 49: 771-4
26. Braden GL, Germain MJ, Mulhern JG, et al. Hemodynamic, cardiac, and electrolyte effects of low-dose aerosolized terbutaline sulfate in asthmatic patients. Chest 1998; 114: 380-7
27. Braun SR, Levy SF. Comparison of ipratropium bromide and albuterol in chronic obstructive pulmonary disease: a three-center study. Am J Med 1991; 91 (4A): 28-32S
28. Buch J, Bundgaard A. Cardiovascular effects of intramuscular or inhaled terbutaline in asthmatics. Acta Pharmacol Toxicol (Copenh) 1984; 54 (3): 183-8
29. Burgess CD, Ayson M, Rajasingham S, et al. The extrapulmonary effects of increasing doses of formoterol in patients with asthma. Eur J Clin Pharmacol 1998; 54: 141-7
30. Burggraaf J, Westendorp RGJ. in't Veen JCCM, et al. Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients. Thorax 2001; 56: 567-9
31. Cazzola M, Imperatore F, Salzillo A, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with pre-existing cardiac arrhythmias and hypoxemia. Chest 1998; 114 (2): 411-5
32. Chan CK, Loke J, Snyder PE, et al. Oral terbutaline augments cardiac performance in chronic obstructive pulmonary disease. Am J Med Sci 1988; 296 (1): 33-8
33. Hall IP, Woodbead MA, Johnston ID. Effect of high-dose salbutamol on cardiac rhythm in severe chronic airflow obstruction: a controlled study. Respiration 1994; 61 (4): 214-8
34. Jartti T, Kaila T, Tahvanainen K, et al. The acute effects of inhaled salbutamol on the β-to-beat variability of heart rate and blood pressure assessed by spectral analysis. Br J Clin Pharmacol 1997; 43 (4): 421-8
35. Marlin GE, Bush DE, Berend N. Comparison of ipratropium bromide and fenoterol in asthma and chronic bronchitis. Br J Clin Pharmacol 1978; 6 (6): 547-9
36. Vathenen AS, Britton JR, Ebden P, et al. High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis 1988; 138 (4): 850-5
37. Wong CS, Pavord ID, Williams J, et al. Bronchodilator, cardiovascular, and hypokalemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990; 336: 1396-9
38. Seccareccia F, Pannozzo F, Dima F, et al. Heart rate as a predictor of mortality: the MATISS Project. Am J Public Health 2001; 91 (8): 1258-63
39. Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002; 19 (5): 936-43
40. Anderson G, Wilkins E, Jariwalla AG. Fenoterol in asthma. Br J Dis Chest 1979; 73 (1): 81-4
41. Bensch G, Lapidus RJ, Levine BE, et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol 2001; 86: 19-27
42. Boyd G. Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group. Eur Respir J 1995; 8 (9): 1494-8
43. Chapman KR, Arvidsson P, Chuchalin AG, et al. The addition of salmeterol 50μg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Can Respir J 2002; 9 (3): 178-85
44. D'Urzo AD, Chapman KR, Cartier A, et al. Effectiveness and safety of salmeterol in nonspecialist practice settings. Chest 2001; 119 (3): 714-9
45. Dahl R, Eamshaw JS, Palmer JB. Salmeterol: a four week study of a long-acting β-adrenoceptor agonist for the treatment of reversible airways disease. Eur Respir J 1991; 4 (10): 1178-84
46. Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164 (5): 778-84
47. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122 (1): 47-55
48. Fitzpatrick MF, Mackay T, Driver H, et al. Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled β2-agonist. BMJ 1990; 301: 1365-8
49. Milgrom H, Skonner DP, Bensch G, et al. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol 2001; 108: 938-45
50. Nathan RA, Seltzer JM, Kemp JP, et al. Safety of salmeterol in the maintenance treatment of asthma. Ann Allergy Asthma Immunol 1995; 75 (3): 243-8
51. Nielsen LP, Pedersen B, Faurschou P, et al. Salmeterol reduces the need for inhaled corticosteroid in steroid-dependent asthmatics. Respir Med 1999; 93 (12): 863-8
52. Pearlman DS, Stricker W, Weinstein S, et al. Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Ann Allergy Asthma Immunol 1999; 82 (3): 257-65
53. Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled β2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163 (5): 1087-92
54. Richter B, Bender R, Berger M. Effects of on-demand β2-agonist inhalation in moderate-to-severe asthma: a randomized controlled trial. J Intern Med 2000; 247 (6): 657-66
55. Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121 (4): 1058-69
56. Siegel SC, Katz RM, Rachelefsky GS, et al. A placebo-controlled trial of procaterol: a new long-acting oral β2-agonist in bronchial asthma. J Allergy Clin Immunol 1985; 75: 698-705
57. Spector SL, Garza Gomez M. Dose-response effects of albuterol aerosol compared with isoproterenol and placebo aerosols: response to albuterol, isoproterenol, and placebo aerosols. J Allergy Clin Immunol 1977; 59 (4): 280-6
58. Yates DH, Sussman HS, Shaw MJ, et al. Regular formoterol treatment in mild asthma: effect on bronchial responsiveness during and after treatment. Am J Respir Crit Care Med 1995; 152 (4 Pt 1): 1170-4
59. Haffner CA, Kendall MJ. Metabolic effects of β2-agonists. J Clin Pharm Ther 1992; 17 (3): 155-64
60. Lockett M. Dangerous effects of isoprenaline in myocardial failure. Lancet 1963; II: 104-6
61. Kurland G, Williams J, Lewiston NJ. Fatal myocardial toxicity during continuous infusion intravenous isoproterenol therapy in asthma. J Allergy Clin Immunol 1979; 63: 407-11
62. Neville E, Corris PA, Vivian J, et al. Nebulized salbutamol and angina. BMJ 1982; 285: 796-7
63. Higgins RM, Cookson WOCM, Lane SM, et al. Cardiac arrhythmias caused by nebulized β-agonist therapy. Lancet 1987; 2 (8563): 863-4
64. Robin ED, McCauley R. Sudden cardiac death in bronchial asthma, and inhaled β-adrenergic agonists. Chest 1992; 101 (6): 1699-702
65. Raper R, Fisher M, Bihari D. Profound, reversible, myocardial depression in acute asthma treated with high-dose catecholamines. Crit Care Med 1992; 20 (5): 710-2
66. Tandon MK. Cardiopulmonary effects of fenoterol and salbutamol aerosols. Chest 1980; 77 (3): 429-31
67. Coleman JJ, Vollmer WM, Barker AF, et al. Cardiac arrhythmias during the combined use of β-adrenergic agonist drugs and theophylline. Chest 1986; 90 (1): 45-51
68. Windom HH, Burgess CD, Siebers RWL, et al. The pulmonary and extrapulmonary effects of inhaled β-agonists in patients with asthma. Clin Pharmacol Ther 1990; 48: 296-301
69. Lipworth B, Clark RA, Dhillon DP, et al. Comparison of the effects of prolonged treatment with low and high doses of inhaled terbutaline on β-adrenoceptor responsiveness in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1990; 142: 338-42
70. Newhouse MT, Chapman KR, McCallum AL, et al. Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute severe asthma. Chest 1996; 110: 595-603
71. Au DH, Curtis JR, Psaty BM. Risk of myocardial ischemia and β-adrenoceptor agonists. Ann Med 2001; 33: 287-90
72. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to develop guidelines for the management of patients with supraventricular arrhythmias). Circulation 2003; 108 (15): 1871-909
73. Julius S. Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. Eur Heart J 1998; 19 Suppl. F: F14-8
74. Julius S, Palatini P, Nesbitt SD. Tachycardia: an important determinant of coronary risk in hypertension. J Hypertens 1998; 16 Suppl. 1: S9-15
75. Umana E, Solares CA, Alpert MA. Tachycardia-induced cardiomyopathy. Am J Med 2003; 114 (1): 51-5
76. Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-Up Study. Am Heart J 1991; 121 (1 Pt 1): 172-7
77. Berton GS, Cordiano R, Palmieri R, et al. Heart rate during myocardial infarction: relationship with one-year global mortality in men and women. Can J Cardiol 2002; 18 (5): 495-502
78. Jouven X, Zureik M, Desnos M, et al. Resting heart rate as a predictive risk factor for sudden death in middle-aged men. Cardiovasc Res 2001; 50 (2): 373-8
79. Benetos A, Rudnichi A, Thomas F, et al. Influence of heart rate on mortality in a French population: role of age, gender and blood pressure. Hypertension 1999; 33: 44-52
80. Palatini P, Casiglia E, Julius S, et al. High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med 1999; 159 (6): 585-92
81. Palatini P, Thijs L, Staessen JA, et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002; 162 (20): 2313-21
82. Nordrehaug JE, Johanssen KA, von der Lippe G. Serum potassium concentration as a risk factor of ventricular arrhythmias early in acute myocardial infarction. Circulation 1985; 71 (4): 645-9.
83. Bremner P, Burgess CD, Crane J, et al. Cardiovascular effects of fenoterol under conditions of hypoxaemia. Thorax 1992; 47 (10): 814-7
84. Lipwotth B. Revisiting interactions between hypoxaemia and β2-agonists in asthma. Thorax 2001; 56: 506-7
85. Brodde O-E, Howe U, Egerszegi S, et al. Effect of prednisolone and ketotifen on β2-adrenoceptors in asthmatic patients receiving β2-bronchodilatora. Eur J Clin Pharmacol 1988; 34: 145-50
86. Rodrigo GJ, Rodrigo C. Continuous vs intermittent β-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis. Chest 2002; 122 (1): 160-5
87. Lipworth BJ. Risks versus benefits of inhaled β2-agonists in the management of asthma. Drug Saf 1992; 7 (1): 54-70
88. Taylor DR, Sears M, Cockcroft DW. The β-agonist controversy. Med Clin North Am 1996; 80 (4): 719-48
89. Emilien G, Maloteaux JM. Current therapeutic uses and potential of β-adrenergic agonists and antagonists. Eur J Clin Pharmacol 1998; 53: 319-404
90. Benson RL, Perlman F. Clinical aspects of epinephrine by inhalation. J Allergy Clin Immunol 1948; 19: 129-40
91. Committee on Safety of Drugs. Aerosols in asthma. Issue 5. LMCM, 1967.
92. Dodds WN, Soler NO, Thompson H. Deaths in asthma [letter]. BMJ 1975; 4: 345
93. Kraan J, Koeter GH, vd Mark TW, et al. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol 1985; 76; 628-36
94. Sears MR, Taylor DR, Print CG, et al. Regular inhaled β-agonist treatment in bronchial asthma. Lancet 1990; 336 (8728): 1391-6
95. Wahedna I, Wong CS, Wisniewski AF, et al. Asthma control during and after cessation of regular β2-agonist treatment Am Rev Respir Dis 1993; 148 (3): 707-12
96. Spitzer WO, Suissa S, Ernst P, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326 (8): 501-6
97. US Food and Drug Administration. Study of asthma drug halted. FDA Talk Paper; 2003 Jan 23: T-03-06
98. Salpeter SR, Ormiston TM, Salpeter EE. A meta-analysis of respiratory tolerance to regular β2-agonist use in patients with asthma. Ann Intern Med. In press
99. Brophy IM, Joseph L, Rouleau JL. β-blockers in congestive heart failure. Ann Intern Med 2001; 134: 550-60
100. Salpeter SR, Ormiston TM, Salpeter EE, et al. Cardioselective β-blockers for chronic obstructive pulmonary disease: a metaanalysis. Respir Med 2003; 97 (10): 1094-101
101. Salpeter S, Ormiston T, Salpeter E. Cardioselective β-blocker use in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002; 137: 715-25